Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $111.6 million.

  • Rocket Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1849.29% to $111.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.6 million, marking a year-over-year increase of 1849.29%. This contributed to the annual value of $94.8 million for FY2024, which is 1285.43% up from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Shares Outstanding (Weighted Average) of $111.6 million as of Q3 2025, which was up 1849.29% from $111.0 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $111.6 million during Q3 2025, with a 5-year trough of $61.6 million in Q1 2021.
  • In the last 5 years, Rocket Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $80.5 million in 2023 and averaged $81.7 million.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Shares Outstanding (Weighted Average) soared by 374.48% in 2022 and then soared by 2479.87% in 2023.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $63.2 million in 2021, then increased by 7.77% to $68.1 million in 2022, then increased by 23.27% to $84.0 million in 2023, then increased by 12.85% to $94.8 million in 2024, then grew by 17.68% to $111.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $111.6 million for Q3 2025, versus $111.0 million for Q2 2025 and $110.1 million for Q1 2025.